Global Retirement Partners LLC Buys New Holdings in Danaher Corporation $DHR

Global Retirement Partners LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,849 shares of the conglomerate's stock, valued at approximately $14,292,000.

• The Often-Missed Corner of Healthcare That Wall Street Is Loving

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Main Street Group LTD purchased a new stake in shares of Danaher during the 1st quarter worth about $25,000. JPL Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth approximately $25,000. Elevated Capital Advisors LLC purchased a new position in Danaher in the fourth quarter valued at approximately $26,000. WFA of San Diego LLC purchased a new position in Danaher in the second quarter valued at approximately $26,000. Finally, Hilton Head Capital Partners LLC acquired a new position in Danaher during the fourth quarter valued at approximately $27,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HSBC decreased their price objective on shares of Danaher from $270.00 to $230.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. Royal Bank Of Canada raised their target price on shares of Danaher from $200.00 to $215.00 and gave the company an "outperform" rating in a research note on Wednesday, July 22nd. JPMorgan Chase & Co. decreased their price target on shares of Danaher from $275.00 to $245.00 and set an "overweight" rating for the company in a research report on Wednesday, April 22nd. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Finally, UBS Group reduced their price objective on Danaher from $270.00 to $250.00 and set a "buy" rating on the stock in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $228.91.

• An AI Play Hiding in Plain Sight: A Look at Johnson Controls

Get Our Latest Stock Report on DHR

Danaher Trading Up 0.0%

NYSE DHR opened at $202.51 on Monday. The stock has a market cap of $142.37 billion, a P/E ratio of 35.97, a PEG ratio of 2.52 and a beta of 0.78. The company's fifty day simple moving average is $193.14 and its 200-day simple moving average is $192.91. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

• 3 Stocks Offering Strong Value and Stability

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the business earned $0.77 EPS. The business's revenue was up 5.5% on a year-over-year basis. Equities research analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Profile

(Free Report)

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Read More

• Five stocks we like better than Danaher
• The Metals Company’s Big Bet Now Comes Down to a License
• OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
• Meta and Tesla Are Rebounding From Oversold Levels—Now What?
• AMG’s Alternatives Boom Powers Record Growth

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here